Vericiguat in Heart Failure With Reduced Ejection Fraction With High Natriuretic Peptides: A Case of Too Little, Too Late?
- PMID: 33039450
- DOI: 10.1016/j.jchf.2020.09.001
Vericiguat in Heart Failure With Reduced Ejection Fraction With High Natriuretic Peptides: A Case of Too Little, Too Late?
Keywords: NT-proBNP; clinical trial; vericiguat.
Conflict of interest statement
Author Relationship With Industry Dr. Cunningham is supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant (T32HL094301-10). Dr. Jhund’s employer, the University of Glasgow, has been paid for his time working on PARADIGM-HF and PARAGON-HF by Novartis and on DAPA-HF and DELIVER by AstraZeneca; has received speaker, consulting, and advisory board fees from AstraZeneca, Novartis, and Boehringer Ingelheim; and has received research funding from Boehringer Ingelheim.
Comment on
-
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.JACC Heart Fail. 2020 Nov;8(11):931-939. doi: 10.1016/j.jchf.2020.08.008. Epub 2020 Oct 7. JACC Heart Fail. 2020. PMID: 33039447 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials